Dr. Lutzker on OX40 Agonist in Patients With Refractory Solid Tumors

Stuart Lutzker, MD, PhD
Published: Monday, May 23, 2016

Stuart Lutzker, MD, PhD, vice president of BioOncology Exploratory Clinical Development, Genentech, discusses results of the first-in-human study of OX40 agonist in patients with refractory solid tumors.

OX40 is designed to provide co-stimulatory signals for T cells which can hopefully expand the pool of T-effector cells to treat disease, both as a single agent or in combination with atezolizumab, Lutzker explains.

Results of the phase I dose-escalation study show that were no dose-limiting toxicities in the 70 patients who were enrolled in the study. The majority of adverse events were grade 1/2, Lutzker says. Because of these findings, a phase Ib combination study with OX40 and atezolizumab is ongoing.
 
Stuart Lutzker, MD, PhD, vice president of BioOncology Exploratory Clinical Development, Genentech, discusses results of the first-in-human study of OX40 agonist in patients with refractory solid tumors.

OX40 is designed to provide co-stimulatory signals for T cells which can hopefully expand the pool of T-effector cells to treat disease, both as a single agent or in combination with atezolizumab, Lutzker explains.

Results of the phase I dose-escalation study show that were no dose-limiting toxicities in the 70 patients who were enrolled in the study. The majority of adverse events were grade 1/2, Lutzker says. Because of these findings, a phase Ib combination study with OX40 and atezolizumab is ongoing.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x